+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


KOL Perspectives: Histologic Healing in Crohn's disease

  • ID: 4701804
  • Drug Pipelines
  • July 2018
  • Region: Global
  • 21 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4



This KOL Insight briefing focuses on KOLs views of Histologic Healing in Crohn’s disease.

Questions topics -
  • Use of histological assessment in clinical trials and practice in Crohn’s disease
  • Extrapolation of UC histology to UC
  • Barriers to adoption of histology assessment in Crohn’s disease
  • Impact of histological data in therapy choice in Crohn’s diseaseꟷViews on use of Geboes as an endpoint in Crohn’s disease
  • Views on Phase II sub-analysis data for filgotinib
Key Highlights
  • Majority of KOLs state that histologic healing is not used to assess Crohn’s disease patients in clinical practice
  • Main barriers to adoption of histologic healing identified by KOLs include difficulty in accessing meaningful biopsy locations, as well as lack of data surrounding histology as a treatment goal
  • Data showing moderate correlation between endoscopy and histology in Phase II does not impact on views of filgotinib efficacy.
  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our IBD key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
  • 5 Europe-based & 5 N. America-based
  • Interviews performed during Q2 2018
KOL data is analyzed to produce -
  • Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts
Reasons to Buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on Histologic Healing in Crohn’s disease
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Note: Product cover images may vary from those shown
2 of 4


  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications
  • Appendix
Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Gilead
  • Celgene
Note: Product cover images may vary from those shown